Leukemia Clinical Trials

Showing 201-220 of 8,366 trials

Immune and Genomic Markers in ALK+ NSCLC

NCT04881916

The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)

Anaplastic Lymphoma Kinase Gene TranslocationNon-Small Cell Lung Cancer

Massachusetts General Hospital100 participantsStarted Dec 2021

Boston, Massachusetts, United States

RECRUITINGNA

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

NCT06487078

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context

ALK+ Non-Small-Cell Lung Carcinoma

Pfizer90 participantsStarted Jan 2025

Paris, Paris, France • Lyon, France • Reims, France +1 more locations

RECRUITINGPhase 1/2

Co-administration of CART22-65s and huCART19 for B-ALL

NCT05674175

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma

Stephan Grupp MD PhD93 participantsStarted Jan 2023

Philadelphia, Pennsylvania, United States

Immune and Genomic Markers in ALK+ NSCLC

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Co-administration of CART22-65s and huCART19 for B-ALL

Related Searches

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

Little NIRVANA for Pediatric Pain and Anxiety

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)